News
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Chemomab Therapeutics Announces Third Quarter 2021 Financial Results and Provides a Corporate UpdateNovember 12, 2021Expands Senior Management Team While Advancing Two Independent Phase 2 Trials and Preparing to Initiate a Third in Early 2022- November 10, 2021--New Preclinical Data Further Supports Ability of CM-101 to Break the Vicious Cycle of Inflammation and Fibrosis in Primary Sclerosing Cholangitis--
November 08, 2021Seasoned veteran brings Chemomab three decades of diverse life sciences industry experience- October 26, 2021Live Event featuring Dr. Dinesh Khanna to be Held Wednesday, November 3rd from 10:00 am - 11:00 am ET
- September 27, 2021-Collaboration will study how CCL24, a soluble protein involved in profibrotic and proinflammatory processes, contributes to the vascular damage related to systemic sclerosis (SSc)-
- September 02, 2021Dr. Adi Mor continues as Chief Scientific Officer, directing scientific strategy and overseeing R&D operations
-
September 01, 2021
- Chemomab Therapeutics Announces Second Quarter 2021 Financial Results and Provides a Business UpdateAugust 13, 2021- CM-101 Phase 2a trials in PSC and liver fibrosis continue to enroll patients with data expected in 2022 -
-
June 23, 2021AGC Biologics to manufacture CM-101 for Phase II/III trials at their Copenhagen facility